Company

Partner

Amount (US$M)

Details

Date

Total: $41.07M (Year-to-date: $756.55M)

Basilea Pharmaceutica Ltd. (Basel, Switzerland)

Astellas Pharma Inc. (Tokyo)

$5.07

U.S. sales of Cresemba (isavuconazole), an antifungal treatment, have triggered the first sales milestone payment from Astellas; Basilea is due to receive CHF5M (US5.07M)

10/24/17

Cadent Therapeutics Inc. (Cambridge, Mass.)

Novartis AG (Basel, Switzerland)

ND

Following the start of a phase I trial concerning a subtype selective NMDA receptive negative allosteric modulator (NAM) to treat treatment-resistant depression; Novartis has obtained an exclusive IP license from Cadent for various compounds that selectively modulate NR2B-containing NMDA receptors

10/18/17

Evotec AG (Hamburg, Germany)

Celgene Corp. (Summit, N.J.)

$5.00

For the successful completion of a screening campaign using Evotec's induced pluripotent stem cell-based screening platform

10/11/17

Exelixis Inc. (South San Francisco)

Bristol-Myers Squibb Co. (New York)

$10.00

For BMS' filing of a clinical trial authorization in Europe for a first-in-human study of a RORyt inverse agonist

10/5/17

Fibrogen Inc. (San Francisco)

Astrazeneca plc (London)

$15.00

CFDA accepted the NDA for roxadustat (FG-4592), an oral treatment for anemia in dialysis-dependent chronic kidney disease (CKD) and nondialysis-dependent CKD patients

10/19/17

Infinity Pharmaceuticals Inc. (Cambridge, Mass.)

Verastem Inc. (Boston)

$6.00

For the positive top-line results from the phase III DUO trial testing duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

10/18/17

Innovative Targeting Solutions Inc. (San Francisco)

Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.)

ND

Achieved its fourth milestone in its collaboration using ITS' Hutarg research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer

10/12/17

Sutro Biopharma Inc. (South San Francisco)

Celgene Corp. (Summit, N.J.)

ND

Received an undisclosed manufacturing milestone payment for completing production of STRO-001, an antibody-drug conjugate, using Sutro's cell-free protein synthesis technology; STRO-001 will be tested in clinical trials in patients with multiple myeloma and aggressive and indolent lymphomas starting in the first quarter of 2018

10/12/17


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.